Background: Propofol is one of the most commonly used intravenous induction agents in anesthesia practice due to its rapid onset and smooth recovery profile. However, pain on injection remains a significant drawback, causing discomfort and anxiety to patients. Various pharmacological methods have been evaluated to reduce propofol injection pain. Ketamine, owing to its analgesic and NMDA receptor antagonistic properties, may be effective in low doses for alleviating this pain. Pain on injection of propofol is a common and distressing problem during induction of general anesthesia. Low-dose ketamine, due to its analgesic and NMDA receptor antagonistic properties, has been studied as a pre-treatment to reduce this pain.
Objectives:
Materials and Methods: This prospective, randomized, double-blind study was conducted on 90 patients (ASA I–II) undergoing elective surgeries. Patients were divided into three groups: Control (saline), Ketamine 0.2 mg/kg, and Ketamine 0.3 mg/kg. Pain during propofol injection was assessed using a verbal pain score. Hemodynamic parameters and adverse effects were recorded. Results: Both ketamine groups showed significantly reduced pain compared to the control group. Ketamine 0.3 mg/kg provided superior analgesia without significant adverse effects. Conclusion: Low-dose ketamine, especially at 0.3 mg/kg, is effective and safe in reducing pain associated with propofol injection
Propofol is widely used for induction of anesthesia because of its rapid onset and smooth recovery. However, pain during intravenous injection remains a major drawback, reported in up to 90% of patients. This pain negatively affects patient comfort and satisfaction.
Several strategies have been attempted to reduce propofol injection pain, including use of large veins, cooling or warming propofol, slow injection, and pretreatment with drugs such as lignocaine, opioids, and non-steroidal anti-inflammatory drugs. Among these, lignocaine is most commonly used, but it does not completely abolish the pain in all patients.
Ketamine is a dissociative anesthetic with potent analgesic properties mediated through NMDA receptor antagonism. In sub-anesthetic doses, ketamine provides effective analgesia without producing significant psychomimetic effects. Low-dose ketamine has been used successfully to attenuate pain associated with intravenous injections.
The present study was undertaken to evaluate the efficacy of low-dose ketamine in reducing propofol injection pain and to determine the most effective dose with minimal side effects.
Study Design:- Prospective, randomized, double-blind controlled study.
Study Setting:- Department of Anaesthesiology, tertiary care teaching hospital in India.
Ethical Approval
The study was conducted after approval from the Institutional Ethics Committee and obtaining written informed consent from all patients.
Sample Size:- 90 patients.
Inclusion Criteria
Exclusion Criteria
Grouping
|
Group |
Drug Given |
Dose |
Number of Patients |
|
Group C |
Normal Saline |
— |
30 |
|
Group K0.2 |
Ketamine |
0.2 mg/kg |
30 |
|
Group K0.3 |
Ketamine |
0.3 mg/kg |
30 |
Methodology
Pain Assessment Scale
Verbal Pain Score (VPS):
|
Score |
Description |
|
0 |
No pain |
|
1 |
Mild pain |
|
2 |
Moderate pain |
|
3 |
Severe pain |
Table 1: Demographic Data
|
Parameter |
Group C |
Group K0.2 |
Group K0.3 |
|
Age (years) |
38.6 ± 9.4 |
37.8 ± 8.9 |
39.2 ± 9.1 |
|
Gender (M/F) |
16 / 14 |
15 / 15 |
17 / 13 |
|
Weight (kg) |
61.2 ± 7.3 |
62.1 ± 6.8 |
60.9 ± 7.1 |
Demographic parameters were comparable (p > 0.05).
Table 2: Incidence of Pain on Propofol Injection
|
Pain Score |
Group C |
Group K0.2 |
Group K0.3 |
|
No pain (0) |
4 (13.3%) |
14 (46.7%) |
22 (73.3%) |
|
Mild pain (1) |
8 (26.7%) |
10 (33.3%) |
6 (20%) |
|
Moderate pain (2) |
10 (33.3%) |
4 (13.3%) |
2 (6.7%) |
|
Severe pain (3) |
8 (26.7%) |
2 (6.7%) |
0 (0%) |
Table 3: Comparison of Mean Pain Scores
|
Group |
Mean VPS ± SD |
|
Group C |
2.13 ± 0.81 |
|
Group K0.2 |
0.93 ± 0.74 |
|
Group K0.3 |
0.33 ± 0.55 |
p < 0.001 (statistically significant)
Table 4: Hemodynamic Parameters
|
Parameter |
Group C |
Group K0.2 |
Group K0.3 |
|
Baseline HR (bpm) |
78 ± 6 |
79 ± 7 |
80 ± 6 |
|
Post-injection HR |
82 ± 7 |
81 ± 6 |
83 ± 7 |
|
Baseline MAP (mmHg) |
92 ± 8 |
90 ± 7 |
91 ± 6 |
|
Post-injection MAP |
88 ± 7 |
89 ± 6 |
90 ± 6 |
No clinically significant hemodynamic changes observed.
Table 5: Adverse Effects
|
Adverse Effect |
Group C |
Group K0.2 |
Group K0.3 |
|
Hallucinations |
0 |
0 |
0 |
|
Nausea/Vomiting |
1 |
1 |
1 |
|
Excessive sedation |
0 |
0 |
0 |
The results of this study clearly indicate that low-dose ketamine significantly reduces pain associated with propofol injection. Ketamine 0.3 mg/kg was superior to 0.2 mg/kg in reducing both incidence and severity of pain.
Ketamine acts by inhibiting NMDA receptors and providing peripheral analgesia. Its use in low doses avoids psychomimetic effects, making it suitable for routine anesthesia practice.
These findings correlate well with previously published Indian and international studies, which report effective attenuation of propofol injection pain with sub-anesthetic ketamine doses.
Low-dose ketamine is an effective and safe method for reducing propofol injection pain. A dose of 0.3 mg/kg IV provides optimal pain relief without significant side effects and can be routinely used during anesthesia induction.